Cramer says Vertex has a drug that may address the 'largest market opportunity in the world'
Publishing timestamp: 2023-10-09 10:54:32
Summary
The article discusses how Vertex Pharmaceuticals is developing a drug to treat acute pain without the use of opioids. The company has late-stage trials underway for the drug, known as VX-548, and if successful, it could be a significant market opportunity. Analysts at Leerink Partners believe that the investment community underappreciates the potential for VX-548. The article also mentions Eli Lilly's drug Mounjaro, which is currently approved for type-2 diabetes but is expected to expand its approved uses to obesity. Cramer has expressed optimism about Mounjaro becoming a best-selling drug.
Sentiment: POSITIVE
Keywords: markets, investingclubsample, eli lilly and co, stock takes, vertex pharmaceuticals inc, biotechnology, breaking news: markets, business news, biotech and pharmaceuticals, investment strategy, jim cramer,